Adage Capital Partners’s Xilio Therapeutics XLO Stock Holding History
Bought
Maintained
Sold
Other funds holding XLO
Adage Capital Partners's XLO Position: Q3 2026 in Review
Adage Capital Partners increased its Xilio Therapeutics (XLO) stake by 317% in Q3 2026, buying an estimated $3.2M and bringing the position to 464,598 shares worth $4.2M. The position accounts for 0.01% of the portfolio, ranked #854.
Adage Capital Partners first reported a position in XLO in Q2 2026 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.
- Adage Capital Partners held 464,598 shares of Xilio Therapeutics worth $4.2M as of Q3 2026.
- Adage Capital Partners bought 353,057 Xilio Therapeutics shares in Q3 2026, an estimated $3.2M.
- Xilio Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q3 2026, its #854 holding.
- Adage Capital Partners first reported a position in Xilio Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.